Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG
Newly published Phase III data show Novartis drug Sandostatin® LAR® reduced risk of disease progression by 66% in advanced NET patients
• Study published in Journal of Clinical Oncology demonstrate antitumor benefit of Sandostatin LAR in advanced midgut neuroendocrine tumor (NET) patients • Data show Sandostatin LAR more than doubled time without tumor progression for median of 14 months versus six months with placebo • National Comprehensive Cancer Network (NCCN) treatment guidelines for advanced NET patients updated based on these data Basel, October 1, 2009 — Data published in the Journal of Clinical Oncology show that patients with advanced neuroendocrine tumors (NET) of the midgut who were treated with Sandostatin® LAR® (octreotide acetate for injectable suspension) experienced a 66% reduction in risk of disease progression versus placebo1. Sandostatin LAR is indicated to treat symptoms associated with functional gastroenteropancreatic neuroendocrine tumors (GEP-NET)2. These data are from the Phase IIIb study PROMID. In the study, patients receiving octreotide LAR more than doubled time without tumor progression for a median of 14 months compared with a median of six months for those who received placebo1. Neuroendocrine tumors are the second most common gastrointestinal malignancy after colon cancer3. These tumors originate from cells that have roles both in the endocrine and nervous systems, and they can be either functioning or non-functioning4. Functioning NET causes the symptoms of carcinoid syndrome, including flushing, diarrhea and wheezing. The majority of NET are non-functioning, which means they do not cause symptoms of carcinoid syndrome3. Once a NET has spread from its point of origin to other parts of the body a patient has few treatment options5. “PROMID is a placebo-controlled, randomized trial that showed octreotide LAR can control tumor growth in all patients with NET of the midgut whether or not they experience symptoms,” said PROMID lead investigator Professor Rudolf Arnold, Philipps-University, Marburg, Germany. “These are promising data for patients with NET who face limited treatment options." The PROMID study showed antitumor benefit in patients with functioning and non- functioning tumors resulting from treatment with octreotide LAR. In an analysis of patients with non-functioning tumors, time to tumor progression for patients receiving octreotide LAR was 28.8 months versus 5.9 months for those on placebo (hazard ratio=0.25 [95% confidence interval 0.10-0.59]). For patients with functioning tumors, time to tumor progression for patients receiving octreotide LAR was 14.3 months and 5.5 months for those on placebo (hazard ratio=0.23 [95% confidence interval 0.09 to 0.57])1. Earlier this year, the NCCN updated its clinical practice guidelines based on the results of PROMID. The NCCN guidelines now recommend the use of octreotide LAR as a
treatment option for all metastatic, unresectable midgut NET patients, regardless of symptoms6. "For more than a decade, octreotide LAR has been a cornerstone of NET treatment for the symptoms of functional gastroenteropancreatic neuroendocrine tumors," said David Epstein, President and CEO, Novartis Oncology, Novartis Molecular Diagnostics. "The findings of the PROMID trial are critical because they show octreotide LAR also has the potential to control tumor growth and provide the benefit of treatment to even more patients with an unmet medical need." About PROMID PROMID (Placebo-controlled, double-blind, prospective Randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine MIDgut tumors) is a Phase IIIb study conducted at 18 sites in Germany to evaluate the antitumor effect of octreotide LAR in patients regardless of symptoms. The study included 85 patients who were treated with either octreotide LAR or placebo until tumor progression. All participants were treatment-naïve, had locally inoperable or metastatic NET with the primary tumor in the midgut and were without curative therapeutic options. Novartis provided funding for this trial. The results of the pre-planned interim analysis now published in the Journal of Clinical Oncology were first presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO GI) in January. An updated analysis with longer patient follow-up was presented earlier this year at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. The updated results confirm that octreotide LAR, when compared to placebo, more than doubled time without tumor growth (15.6 months vs. 5.9 months) and reduced the risk of disease progression by 67% (hazard ratio=0.33 with 95% confidence interval 0.19 to 0.55; P=0.000017)7. The safety profile observed in the PROMID study was consistent with that seen in previous studies of octreotide LAR. The most frequently observed serious adverse events affected the gastrointestinal tract (octreotide LAR arm: n=6, placebo arm n=8), the hematopoetic system (octreotide LAR arm: n=5, placebo arm n=1) and the general health status (fatigue, fever; octreotide LAR arm: n=8, placebo arm n=2). Serious adverse events occurred in 11 octreotide LAR-treated patients and 10 placebo recipients. Discontinuation of treatment due to adverse effects occurred in five of 42 patients in the octreotide LAR and in none of the 43 patients in the placebo arm. About neuroendocrine tumors There are many different types of NET, which can occur throughout the body8. However, most are found in the digestive system and are collectively called GEP-NET4,9. Carcinoid tumors and pancreatic NET are types of GEP-NET3. Although it is considered a rare cancer, the incidence of NET is on the rise and more prevalent than originally reported8. About Sandostatin LAR Sandostatin LAR is a long-acting, injectable depot formulation of octreotide acetate that is indicated for the treatment of acromegaly for patients in whom surgery or radiotherapy is inappropriate or ineffective; for patients until radiotherapy becomes fully effective; and for the relief of symptoms associated with functional GEP-NET. Octreotide has been used to treat the clinical syndromes associated with NET and substantially reduces, and in many cases can control, growth hormone and/or normalize IGF-1 levels in patients with acromegaly, a disease caused by a GH-secreting pituitary adenoma1. Sandostatin LARimportant safety information Patients who have a known hypersensitivity to octreotide or to any of the excipients should not take Sandostatin LAR. Dose adjustments of drugs, such as beta-blockers, calcium channel blockers or agents to control fluid and electrolyte balance may be necessary. Caution should be used in patients with insulinomas and in patients with
diabetes mellitus. Thyroid function should be monitored in patients receiving prolonged treatment with octreotide. Patients receiving Sandostatin LAR should receive periodic examination of the gallbladder; and patients who have a history of vitamin B12 deprivation should have their vitamin B12 levels monitored. Caution should be used in patients who are pregnant; patients should be advised to use adequate contraception, if necessary. Patients should not breast-feed during Sandostatin LAR treatment. The use of Sandostatin LAR may increase the bioavailability of bromocriptine, impair intestinal absorption of cyclosporin and delay that of cimetidine. Drugs mainly metabolized by CYP3A4 and drugs with a low therapeutic index should be used with caution1. The most common (≥ 1/10) adverse drug reactions in clinical studies with Sandostatin LAR were diarrhea, abdominal pain, nausea, constipation, flatulence, headache, cholelithiasis, hyperglycemia and injection-site localized pain. Common (≥ 1/100, < 1/10) adverse drug reactions were dyspepsia, vomiting, abdominal bloating, steatorrhea, loose stools, discoloration of feces, dizziness, hypothyroidism, thyroid dysfunction (e.g., decreased thyroid stimulating hormone, decreased Total T4 and decreased Free T4), cholecystitis, biliary sludge, hyperbilirubinemia, hypoglycemia, impairment of glucose tolerance, anorexia, elevated transaminase levels, pruritus, rash, alopecia, dyspnea and bradycardia1. Uncommon (≥ 1/1000, <1/100) adverse drug reactions included dehydration and tachycardia. The following adverse reactions have been reported postmarketing: anaphylaxis, allergy/hypersensitivity reactions, urticaria, acute pancreatitis, acute hepatitis without cholestasis, cholestatic hepatitis, cholestasis, jaundice, cholestatic jaundice, arrhythmia, increased alkaline phosphatase levels and increased gamma glutamyl transferase levels1. Disclaimer The foregoing release contains forward-looking statements that can be identified by terminology such as “risk,” “promising,” “potential,” or similar expressions, or by express or implied discussions regarding potential new indications or labeling for Sandostatin LAR or regarding potential future revenues from Sandostatin LAR. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Sandostatin LAR to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Sandostatin LAR will be submitted or approved for any additional indications or labeling in any market. Nor can there be any guarantee that Sandostatin LAR will achieve any particular levels of revenue in the future. In particular, management’s expectations regarding Sandostatin LAR could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in each of these areas. In 2008, the Group’s continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 full-time- equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com. References 1.
Journal of Clinical Oncology. online August 24, 2009. http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2009.22.8510.
Prescribing information for Sandostatin LAR
Modlin IM, et al. “Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl
Cancer Inst. 2008 Sept 7;100(18):1282-1289.
Kloppel G, Perren A, Heitz PU The Gastroenteropancreatic Neuroendocrine Cell System and Its Tumors: The WHO Classification. Ann. of the New York Acad of Sci. 2006 Jan 16 2005; 1014:13-27.
Halfdanarson, et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Annals of Onc 19: 1727-1733, 2008.
Update.http://www.nccn.org/network/business_insights/flash_updates/2009-05-28.asp. Last accessed July 2009.
Arnold R, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. Abstract # 4508. American Society of Clinical Oncology 2009 Annual Meeting, Orlando, FL.
Yao, J. One Hundred Years After "Carcinoid:" Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. Journal of Clinical Oncology. June 20 2009; vol. 26, number 18.
American Cancer Society. Detailed Guide: Gastrointestinal Carcinoid Tumors. What are the key statistics about gastrointestinal
http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_gastrointestinal_carcinoid_tumors_14.asp?rnav=cri . Accessed July 2009
Novartis Media Relations
Central media line : +41 61 324 2200 Eric Althoff Denise Brashear
eric.althoff@novartis.com e-mail: media.relations@novartis.com Novartis Investor Relations Central phone: North America:
An update on “Bleeders” and that reported in Japan, Britain and South Africa, and less than that reported in Singapore, Hong Kong Defining a “bleeder”. and the USA. definition of a “bleeder” in various world. In Australia, bleeding is defined as the appearance of blood indicate that some degree of EIPH at both nostrils, irrespective of the ma
Annotated Risk Indicators Associated with Permanent, Congenital, Delayed-Onset or Progressive Hearing Loss in Childhood Risk indicators that are marked with a " " are associated with delayed-onset hearing loss. 1. Any caregiver concern regarding hearing, speech, language, or developmental delay. 2. A family history of permanent childhood hearing loss. 3. A newborn intens
